More information
Description
Breast cancer screening in EU contries is only age-based but mortality could be decreased by around 20% if screening programmes would consider AnteBC individual test results. However, as European healthcare markets are heavily fragmented and regulated, population-wide adoption of a new solution requires public reimbursement to end-users. Clinical adoption requires proof of clinical utility and feasibility of its use in the local medical setting. Project promoter OÜ Antegenes has registered a polygenic breast cancer (BC) risk test, AnteBC as an CE-certified medical device.
The General Objective of the project is to collect clinical utility and performance evidence on the Antegenes breast cancer risk test (AnteBC) in several scientific studies, to drive the clinical adoption with a feasibility pilot of AnteBC in Norwegian medical settings and to generate technical documentation for preparing a Norwegian reimbursement application.
Project consortium brings in the best scientific expertise within Norway to assess the performance and utility of our tests for the local settings, one of the largest hospital trusts to apply this in a clinical practice and a well-connected cancer knowledge cluster to communicate the project outputs to drive further engagement in the local stakeholder community. A novel healthcare application with Estonian source in the Norwegian health system provides a platform for developing mutual professional partnerships between all the project partners and also with external parties engaged via dissemination activities. As Antegenes continues developing their services in Norway, the OCC will be a solid link with the Estonian medtech knowledge hubs and will continue acting as a mediator of knowledge between all counterparts to service future cooperation between various stakeholders of precision medicine.